Protara Therapeutics, Inc.

On November 4, 2026, the Company entered into an asset purchase agreement for manufacturing-related assets, including an assembled workforce, inventory, intellectual property, contracts, equipment, permits, regulatory documentation and records, for its product candidate, TARA-002, from Novex, which closed simultaneously with the signing of the asset purchase agreement. Pursuant to the asset purchase agreement, the aggregate purchase price was $8.75 million, subject to certain credits and adjustments. The Company completed the acquisition to bring manufacturing in-house and secure dedicated manufacturing capacity ahead of a potential commercial launch. As part of the transaction, the Company also entered into certain ancillary agreements, including a transition services agreement, and a lease of a research and manufacturing facility with an affiliate of Novex. See Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview” of this Quarterly Report on Form 10-Q, which is incorporated by reference herein, for more information.

During the three months ended September 30, 2026, no director or officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.